Copy Link Print Information

Ulixertinib

(Synonyms: BVD-523; VRT752271)
48 Cited Publications
Customer Review

Based on 48 publication(s) in Google Scholar

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.

For research use only. We do not sell to patients.

  • Purity: 99.92%
  • CAS No.: 869886-67-9
  • Formula: C21H22Cl2N4O2
  • Molecular Weight:433.33
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Ulixertinib Chemical Structure
    Ulixertinib Chemical Structure
  • Experimental Validation Results for Ulixertinib
  • Experimental Validation Results for Ulixertinib
  • Experimental Validation Results for Ulixertinib
  • Experimental Validation Results for Ulixertinib
  • Experimental Validation Results for Ulixertinib
  • Experimental Validation Results for Ulixertinib
CAS No.: 869886-67-9
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Ulixertinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Ulixertinib

More
Customer Validation & Images
WBCell Migration/Invasion AssayIHCIn Vivo Efficacy Study
  • IHC
  • WB
  • WB
  • Cell Migration/Invasion Assay
  • In Vivo Efficacy Study
  • WB

All ERK Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Ulixertinib Chemical Structure
    Ulixertinib Chemical Structure
    1/16
  • 1/16

    Ulixertinib purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2024 Jun;31(6):804-819. [Abstract]

    Customer Validation
     Representative images and quantifications showing CD45R, CD8, CD4, and FOXP3 immunostainings in lung sections of TMX-administered Erk and Erk;BRAFV600E mice treated with Ulixertinib (200 mg/kg/day; p.o. twice a day).

  • 1/16

    Ulixertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 19;14(1):2859. [Abstract]

    Customer Validation
     IB analysis of WCL and GST pull-down precipitates from HEK293T cell lysates with ectopic expression of PD-1-cHA incubated with recombinant GST-USP5 protein. Cells were treated with 1 μM Ulixertinib for 24 h.

  • 1/16

    Ulixertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Nov 2;14(1):6997. [Abstract]

    Customer Validation
     Western blot analyses in MCF-7 cells treated with tamoxifen, GebR-7b or the ERK inhibitor, Ulixertinib for 20 min or 24 hours in combination with E2.

  • 1/16

    Ulixertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Jul 14;13(1):4078. [Abstract]

    Customer Validation
     Transwells were pretreated with fibronectin and sEVs from B16F10 cells with or without BVD-523 (2 μM; 24 h). Percentages of transmigrated mouse CD8+ T cells induced by CXCL9 were accessed.

  • 1/16

    Ulixertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Jul 14;13(1):4078. [Abstract]

    Customer Validation
     Growth of B16F10 tumors expressing HRSWT, HRSS345A, or HRSS345D treated with vehicle, anti-PD-1, BVD-523 (BVD), or anti-PD-1 plus BVD-523 (50 mg/kg; p.o. twice daily) as indicated.

  • 1/16

    Ulixertinib purchased from MedChemExpress. Usage Cited in: Innate Immun. 2020 Aug;26(6):505-513. [Abstract]

    Customer Validation
     The protein levels of p-ERK1/2, ERK1/2, p-RSK, and RSK are measured by Western blotting.

  • Ulixertinib